首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial
【2h】

A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial

机译:I期高血压患者利尿剂和血管紧张素受体阻滞剂之间的比较(PREVER治疗试验):一项随机双盲对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundCardiovascular disease is the leading cause of death in Brazil, and hypertension is its major risk factor. The benefit of its drug treatment to prevent major cardiovascular events was consistently demonstrated. Angiotensin-receptor blockers (ARB) have been the preferential drugs in the management of hypertension worldwide, despite the absence of any consistent evidence of advantage over older agents, and the concern that they may be associated with lower renal protection and risk for cancer. Diuretics are as efficacious as other agents, are well tolerated, have longer duration of action and low cost, but have been scarcely compared with ARBs. A study comparing diuretic and ARB is therefore warranted.
机译:背景技术心血管疾病是巴西的主要死亡原因,而高血压是其主要危险因素。药物治疗预防重大心血管事件的益处一直得到证实。血管紧张素受体阻滞剂(ARB)一直是全世界高血压治疗中的首选药物,尽管尚无任何证据表明它比老年药物更具有优势,并且担心它们可能与较低的肾脏保护作用和癌症风险有关。利尿药与其他药物一样有效,耐受性好,作用时间更长,成本较低,但与ARB相比几乎没有。因此,有必要对利尿剂和ARB进行比较。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号